In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile / F.R. Mauro, S. Molica, L. Laurenti, A. Cortelezzi, A.M. Carella, F. Zaja, A. Chiarenza, F. Angrilli, F. Nobile, R. Marasca, C. Musolino, M. Brugiatelli, A. Piciocchi, M. Vignetti, P. Fazi, G. Gentile, M.S. De Propris, I. Della Starza, M. Marinelli, S. Chiaretti, I. Del Giudice, M. Nanni, F. Albano, A. Cuneo, A. Guarini, R. Foà, Gruppo Italiano Malattie EMatologiche dell’Adulto. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - 38:2(2014 Feb), pp. 198-203. [10.1016/j.leukres.2013.11.009]
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
A. Cortelezzi;
2014
Abstract
In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0145212613003974-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.19 MB
Formato
Adobe PDF
|
1.19 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
